AB569: Treatment for Drug Resistant Bacterial Infections
AB569 is a new drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs. It also has potential to be modified for use in other indications, including adaptation as a topical cream for bacterial skin infections.
AB569 has a mechanism of action that differs from the mechanism of action of antibiotics. AB569 has orphan drug status from the U.S. FDA for the treatment of Pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. AB569 has orphan medicinal product designation from the European Medicines Agency for the treatment of cystic fibrosis.
Respiratory Pseudomonas Aeruginosa Infections
Two deadly diseases, cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), are exacerbated by airway bacterial infections that significantly impact the overall quality of patient’s lives. There are approximately 40,000 CF patients and over 14 million individuals diagnosed with COPD in the United States. In both diseases, antibiotic resistant Gram-negative bacteria, such as Pseudomonas aeruginosa (P. aeruginosa), often constitute a significant and problematic cause of the pulmonary exacerbations that result in frequent hospitalizations of these patients.
In particular, the mucoid form of P. aeruginosa is a very challenging infection to treat due to its high resistance to both antibiotics and phagocyte–mediated killing. Once patients present with the mucoid form of P. aeruginosa, their overall lung function precipitously declines resulting in a poor prognosis.
AB569 constitutes an innovative method and potential candidate to treat mucoid and non mucoid P. aeruginosa pulmonary infections, as well as other types of bacterial pulmonary infections, that are resistant to traditional antibiotics.